Tribiotic
Natural health product licensed in Canada
- Licence holder
- Arrae Inc.
- NPN or DIN-HM
- 80149673
- Status
- Active licence
- Licence date
- 3 July 2026
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Lactobacillus acidophilus Source : NCFM | 0.5 Milliards d'UFC | Not calculated |
| Lactobacillus acidophilus Source : Lactobacillus acidophilus - Cellule entière | 0.5 Milliards d'UFC | Not calculated |
| Lactococcus lactis Source : Lactococcus lactis - Cellule entière | 18 Milliards d'UFC | Not calculated |
| Lactobacillus acidophilus Source : Lactobacillus acidophilus - Cellule entière | 2 Milliards d'UFC | Not calculated |
| Lactobacillus acidophilus Source : LA-14 | 2 Milliards d'UFC | Not calculated |
| Bifidobacterium animalis subsp. lactis Source : HN019 | 1 Milliards d'UFC | Not calculated |
| Bifidobacterium animalis subsp. lactis Source : BI-07 | 0.5 Milliards d'UFC | Not calculated |
| Bifidobacterium longum subsp. longum Source : Bifidobacterium longum subsp. longum - Cellule entière | 12.5 mg | Not calculated |
| Bifidobacterium longum subsp. longum Source : CECT 7347 (ES1 HT) | 12.5 mg | Not calculated |
| Xylooligosaccharides | 200 mg | Not calculated |
Non-medicinal ingredients
Sucrose, Phosphate de dipotassium, Hypromellose, Extrait de son d'Oryza sativa (Riz), Poudre d'enveloppes d'Oryza sativa (Riz), Gomme arabique, Phosphate de potassium monobasique
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 2 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Could promote a favorable gut flora. Helps support intestinal/gastrointestinal health. Source of Probiotics. Promotes favourable gut flora/intestinal microflora. Reduces whole gut transit time/helps to accelerate intestinal transit time. Supports digestion by reducing transit time. Reduces frequency of functional gastrointestinal symptoms (e.g. constipation, irregularity, flatulence). Promotes bowel movement. Helps provide gentle relief of constipation and/or irregularity.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80149673
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.